RecruitingPhase 2NCT06107686

A Study of YL202 in Selected Patients With Advanced Solid Tumors

A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Enrollment

200 participants

Start Date

Dec 15, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer NSCLC HNSCC Locally Advanced or Metastatic Solid Tumors

Summary

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing YL202, an antibody-drug conjugate (ADC) that targets a protein called HER3 found on many solid tumor cells, in people with advanced cancers including non-small cell lung cancer, breast cancer, head and neck cancer, colorectal cancer, gastric cancer, cervical cancer, ovarian cancer, and others. **You may be eligible if...** - You are 18–75 years old - You have a confirmed advanced or metastatic solid tumor (including lung, breast, head and neck, colorectal, gastric, cervical, or ovarian cancers) - You have at least one measurable tumor outside the brain - Your general health status is good (ECOG 0 or 1) - Your organ function is adequate - Expected survival is at least 3 months **You may NOT be eligible if...** - You have previously received any anti-HER3 therapy (antibodies or ADCs targeting HER3) - You had a serious reaction to a topoisomerase inhibitor (a type of chemo) or similar ADC therapy - You are enrolled in another interventional clinical trial - You recently had major surgery (within 4 weeks), an organ transplant, or bone marrow transplant - You are pregnant or breastfeeding - You have received high-dose steroids or immunosuppressants within 2 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGYL202 should be intravenously infused

For each patient, YL202 should be intravenously infused over 60±10 min.

Locations(82)

Anhui Tumour Hospital

Hefei, Anhui, China

The first affiliated hospital of Anhui Medical University

Hefei, Anhui, China

The Second Hospital of Anhui Medical University

Hefei, Anhui, China

Beijing Cancer hospital

Beijing, Beijing Municipality, China

Beijing Tsinghua Chang Gung Hospital

Beijing, Beijing Municipality, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Chinese First Affiliated Hospital of Army Medical University of the People's Liberation Army

Chongqing, Chongqing Municipality, China

Chongqing University Affiliated Tumor Hospital

Chongqing, Chongqing Municipality, China

The first affiliated hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Xinqiao Hospital of AMU

Chongqing, Chongqing Municipality, China

Xinqiao Hospital

Chongqing, Chongqing Municipality, China

Fujian Tumor Hospital

Fuzhou, Fujian, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

The Sixth Affiliated Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, China

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Meizhou People's Hospital

Meizhou, Guangdong, China

Shantou University Medical College Tumour Hospital

Shantou, Guangdong, China

Guilin Medical College Second Affiliated Hospital

Guilin, Guangxi, China

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

Guangxi Medical University Affiliated Tumour Hospital

Nanning, Guangxi, China

The People's Hospital of Guangxi

Nanning, Guangxi, China

Harbin Medical university cancer hospital

Harbin, Heilongjiang, China

The First Affiliated Hospital Of Henan University&Technology

Luoyang, Henan, China

The First Affiliated Hospital of Nanyang Medical College

Nanyang, Henan, China

Xinxiang Medical University No.1 Affiliated Hospital

Xinxiang, Henan, China

He'nan Cancer Hospital South Gate

Zhengzhou, Henan, China

Henan Provincial Chest Hospital

Zhengzhou, Henan, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

The First Peoples Hospital of Jingzhou

Jingzhou, Hubei, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Tongji Hospital

Wuhan, Hubei, China

Union Hospital Tongji Medical College HuaZhong University of Science Technology

Wuhan, Hubei, China

Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

Wuhan, Hubei, China

Xiangyang Central Hospital

Xiangyang, Hubei, China

Hu'nan Province Cancer Hospital

Changsha, Hunan, China

Hunan Provincial People's Hospital

Changsha, Hunan, China

Xiangya hospital Central South University

Changsha, Hunan, China

The Third People's Hospital of Hunan Province

Yueyang, Hunan, China

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The Affiliated Hospital of Xuzhou medical University

Xuzhou, Jiangsu, China

Xuzhou Central Hospital

Xuzhou, Jiangsu, China

First Affiliated Hospital of Gannan Medical University

Ganzhou, Jiangxi, China

Jiangxi Cancer Hospital

Nanchang, Jiangxi, China

The Affiliated Hospital of NanChang University

Nanchang, Jiangxi, China

The Third Hospital of Nanchang

Nanchang, Jiangxi, China

Jilin Provincial Cancer Hospital

Changchun, Jilin, China

China-Japan Union Hospital of Jilin University

Changchun, Jilin, China

The second Hospital of Dalian Medical University

Dalian, Liaoning, China

Fukuang General Hospital of Liaoning Health Industry Group

Fushun, Liaoning, China

Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China

The First Hospital of China Medical University Physical Examination Center

Shenyang, Liaoning, China

Shandong Cancer Hospital

Jinan, Shandong, China

Jinan Central Hospital Affiliated to Shandong University

Jinan, Shandong, China

Shandong Cancer Hospital

Jinan, Shandong, China

Shandong Provincial Public Health Clinical Center

Jinan, Shandong, China

Affiliated Hospital of Jining Medical University

Jining, Shandong, China

Linyi Cancer hospital

Linyi, Shandong, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Weifang People's Hospital

Weifang, Shandong, China

Huashan Hospital affiliated to Fudan University